{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Slide 25 of a BioNTech presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/25",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Data cutoff: July 23rd 2021; Abbreviations list...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0c20fd5-8c1c-495c-8f40-2d2a0cf73fd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.67,
        "y": 0.5
      },
      "kind": "list",
      "text": "Signs of clinical activity: 6-week assessment for 5/8 patients (4 SD, 1 PD); 3 patients showed tumor shrinkage (-18%, -21%, -27%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3680a579-5571-4820-9a91-e5c46c8525e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.04,
        "y": 0.205
      },
      "kind": "list",
      "text": "Heavily pretreated patients: Testicular, ovarian, endometrial cancer, CUP & soft-tissue sarcoma; 8 patients treated (3 monotherapy DL1/2, 3 combo DL1)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39dd49ff-9033-47c8-876e-67da9e402e24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.205
      },
      "kind": "list",
      "text": "No DLTs or serious drug-related AEs with monotherapy: Manageable CRS, no neurotoxicity, transient IL-6/CRP elevations, transient flu-like symptoms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f21a331-2537-435e-b6cb-7e72bdf277be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.67,
        "y": 0.205
      },
      "kind": "list",
      "text": "Robust CAR-T cell engraftment: Enhanced expansion in 2 patients with liver metastases; elevated ALT, AST, AP; total bilirubin unaffected",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70089410-d4f7-4e6f-9ac1-aabe7167f2ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "SITC 2021 - BNT211 Phase 1/2 trial: Favorable Safety Profile and Encouraging Signs of Efficacy for CLDN6 CAR-T Cells +/- CARVac",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bf08373-4472-4366-9fc2-d9bd1629dcff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "86ee922b-3b38-407a-91d0-e5fba14e6389",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with financial results, outlook, and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8d1b4261-4f6e-4fae-a0eb-442f564dc509",
      "evidence": "The presentation mentions the potential to tackle multiple diseases with different therapeutic modalities",
      "position": 1,
      "objective": "To highlight the potential consequences of not addressing serious diseases",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}